Transparency in Europe: A Quantitative Study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In recent years, European pharmaceutical regulators have increasingly committed to heightening access to raw safety‐related data as part of a wave of transparency initiatives (e.g., providing public Internet‐mediated access to clinical trials data). Yet, the regulators—who are under significant pressure—have not yet benefited from a systematic review of this new policy. In seeking to inject much needed evidence, this article explores the effects of new transparency policies designed to promote meaningful communication of risks and benefits to patients. Results of a cross‐national European survey with respondents from Great Britain, the Netherlands, Spain, France, Germany, and Sweden (N = 5,648) shed light on how patients and the public are likely to react to the regulators’ new transparency policies. The findings demonstrate clear national variations in how European citizens are likely to react and emphasize the need to develop evidence‐based, reasoned transparency policies that integrate benefit‐risk communication. The authors conclude by providing six specific recommendations, informed by the study, that seek to improve the European transparency model both within the medical field and across health, safety, and environmental policy domains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Full Disclosure: The Perils and Promise of Transparency
Fung, A., Graham, M., & Weil, D. (2007) · doi:10.1017/cbo9780511510533 · Cited by 752
Grimmelikhuijsen, S. G., & Meijer, A. J. (2014) · Journal of Public Administration Research and Theory · doi:10.1093/jopart/mus048 · Cited by 678 · cited 1×
“The topic of transparency has received burgeoning academic attention in recent years, resulting in theoretical and increasingly empirical advances.(4,12,35,39,42) Although the modern rhetoric of “transparency” might suggest the term (and concept) is new, several scholars have demonstrated that transparency can be trac…”
Background
Cited by
Vaccine hesitancy and healthcare providers
Paterson, P., Meurice, F., Stanberry, L. R., Glismann, S., Rosenthal, S. L., & Larson, H. J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.042 · Cited by 897
Karafillakis, E., Simas, C., Jarrett, C., Verger, P., Peretti-Watel, P., Dib, F., De Angelis, S., Takacs, J., Ali, K. A., Pastore Celentano, L., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1564436 · Cited by 328
COVID-19: Reflections on trust, tradeoffs, and preparedness
Balog-Way, D. H. P., & McComas, K. A. (2020) · Journal of Risk Research · doi:10.1080/13669877.2020.1758192 · Cited by 214
The problems of increasing transparency on uncertainty
Osman, M., Heath, A. J., & Löfstedt, R. (2018) · Public Understanding of Science · doi:10.1177/0963662517711058 · Cited by 42
“Demands for greater transparency have triggered initiatives that encourage scientists to conduct structured uncertainty analyses (Bouder et al., 2015; Gupta, 2010; Gupta and Mason, 2016; Reffstrup et al., 2010; Rozet et al., 2007; Speigelhalter and Riesch, 2011; Webster et al., 2003) which…”
BackgroundSelf-citation
Metadata
- Authors
- Bouder, F., Way, D., Löfstedt, R., & Evensen, D.
- Venue
- Risk Analysis
- Publisher
- Wiley
- Published
- 2015-05
- Volume
- 35
- Issue
- 7
- Pages
- 1210-1229
- ISSN
- 0272-4332 (ISSN-L)
- 1539-6924
- OpenAlex
- W1895907996
- Cited by
- 64
- References
- 3
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.